Epperly Melissa B, 4

What Happened

• Melissa B. Epperly, a director of Roivant Sciences Ltd. (ROIV), was granted 670 common shares on 2026-04-17. The shares are reported at $0.00 per share (total reported value $0) as an award under the issuer’s Non-Employee Director Compensation Plan. Footnote indicates the award was fully vested as of the grant date, meaning Epperly immediately owned the shares upon grant.
• This was an award/grant (transaction code A), not an open-market purchase or sale—typically routine director compensation rather than a direct buy/sell signal.

Key Details

• Transaction date: 2026-04-17; Filing date (Form 4): 2026-04-21 (filed within the required two business days).
• Price: $0.00 per share; Total reported value: $0.
• Shares received: 670 common shares.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: Award received under the Non-Employee Director Compensation Plan and was fully vested at grant.
• Filing timeliness: Appears timely (filed within SEC Form 4 deadline).

Context

• Director awards are typically compensation for board service and are common; they do not necessarily indicate the director’s view of the company’s near-term prospects.
• Because the award was fully vested on grant, Epperly became the beneficial owner of the shares immediately and could later sell or transfer them—any such transactions would trigger additional Form 4 filings.